Correlation between patient and clinician assessments of depression severity in the PREVENT study
Abstract Background The degree of agreement between patient- and clinician-rated scales of depressive severity varies widely. This study analyzed agreement between commonly used depression rating scales in the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for...
Gespeichert in:
| Veröffentlicht in: | Psychiatry research 2010-05, Vol.177 (1), p.177-183 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 183 |
|---|---|
| container_issue | 1 |
| container_start_page | 177 |
| container_title | Psychiatry research |
| container_volume | 177 |
| creator | Dunlop, Boadie W Li, Thomas Kornstein, Susan G Friedman, Edward S Rothschild, Anthony J Pedersen, Ron Ninan, Philip Keller, Martin |
| description | Abstract Background The degree of agreement between patient- and clinician-rated scales of depressive severity varies widely. This study analyzed agreement between commonly used depression rating scales in the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) trial. Methods The PREVENT trial was a multiphase, randomized, double-blind study of patients with recurrent major depressive disorder. This secondary analysis evaluated acute (10 weeks) and continuation phase (6 months) data. Pearson correlation coefficients at each acute-phase (weekly) and continuation-phase (monthly) visit were calculated for patient-rated (30-item Inventory of Depressive Symptomatology-Self-Rated [IDS-SR30] and clinician-rated (17-item Hamilton Rating Scale for Depression [HAM-D17] and Clinical Global Impressions-Severity [CGI-S]) measures and for response and remission. Results Data from 1,047 patients were analyzed. The respective correlation coefficients at baseline, week 10, and month 6 were: IDS-SR30: HAM-D17: 0.46, 0.75, 0.70; and for IDS-SR30: CGI-S 0.28, 0.67, 0.65. Agreement between IDS-SR30- and HAM-D17-defined remission and response was relatively poor: week 10, 0.52 and 0.34, respectively; month 6, 0.45 and 0.32, respectively. Conclusions These findings suggest that patient-rated measures of depression severity do not correspond strongly with clinician ratings, and are particularly poor prior to the initiation of treatment. |
| doi_str_mv | 10.1016/j.psychres.2010.02.008 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3668786</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165178110000545</els_id><sourcerecordid>S0165178110000545</sourcerecordid><originalsourceid>FETCH-LOGICAL-c621t-7987a7e72e6b83b64b60d5568c5a1f19627d77a3daed6e551791604a8e6f00863</originalsourceid><addsrcrecordid>eNqFUktv1DAQthAVXQp_ofKFY7a2k9jJpQKtFopUUQSFq-XYE9ZL1ok82UX59zhsX3DhZNnzPcbfDCHnnC054_JiuxxwspsIuBQsPTKxZKx6Rha8UiJTXOTPySIBy4yrip-Sl4hbxpjgdf2CnAqWs6Jk-YKYVR8jdGb0faANjL8AAh3SFcJITXDUdj54602gBhEQd6mAtG-pgyG548xDOED040R9oOMG6Ocv6-_rT7cUx72bXpGT1nQIr-_OM_Lt_fp2dZVd33z4uHp3nVkp-JipulJGgRIgmypvZNFI5spSVrY0vOW1FMopZXJnwEkoS65qLllhKpBt-rnMz8jlUXfYNztwNvUZTaeH6HcmTro3Xv9dCX6jf_QHnUtZqT8C8ihgY48YoX3gcqbn0PVW34eu59A1EzpZJ-L5U-cH2n3KCfDmDmDQmq6NJliPjzhRMSmLIuHeHnGQcjp4iBptGoQF5yPYUbve_7-Xy38kjgM03U-YALf9PoY0Bc01JoL-Oq_IvCE8LQcrizL_DTI4urk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Correlation between patient and clinician assessments of depression severity in the PREVENT study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Dunlop, Boadie W ; Li, Thomas ; Kornstein, Susan G ; Friedman, Edward S ; Rothschild, Anthony J ; Pedersen, Ron ; Ninan, Philip ; Keller, Martin</creator><creatorcontrib>Dunlop, Boadie W ; Li, Thomas ; Kornstein, Susan G ; Friedman, Edward S ; Rothschild, Anthony J ; Pedersen, Ron ; Ninan, Philip ; Keller, Martin</creatorcontrib><description>Abstract Background The degree of agreement between patient- and clinician-rated scales of depressive severity varies widely. This study analyzed agreement between commonly used depression rating scales in the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) trial. Methods The PREVENT trial was a multiphase, randomized, double-blind study of patients with recurrent major depressive disorder. This secondary analysis evaluated acute (10 weeks) and continuation phase (6 months) data. Pearson correlation coefficients at each acute-phase (weekly) and continuation-phase (monthly) visit were calculated for patient-rated (30-item Inventory of Depressive Symptomatology-Self-Rated [IDS-SR30] and clinician-rated (17-item Hamilton Rating Scale for Depression [HAM-D17] and Clinical Global Impressions-Severity [CGI-S]) measures and for response and remission. Results Data from 1,047 patients were analyzed. The respective correlation coefficients at baseline, week 10, and month 6 were: IDS-SR30: HAM-D17: 0.46, 0.75, 0.70; and for IDS-SR30: CGI-S 0.28, 0.67, 0.65. Agreement between IDS-SR30- and HAM-D17-defined remission and response was relatively poor: week 10, 0.52 and 0.34, respectively; month 6, 0.45 and 0.32, respectively. Conclusions These findings suggest that patient-rated measures of depression severity do not correspond strongly with clinician ratings, and are particularly poor prior to the initiation of treatment.</description><identifier>ISSN: 0165-1781</identifier><identifier>EISSN: 1872-7123</identifier><identifier>DOI: 10.1016/j.psychres.2010.02.008</identifier><identifier>PMID: 20304503</identifier><identifier>CODEN: PSRSDR</identifier><language>eng</language><publisher>Kidlington: Elsevier Ireland Ltd</publisher><subject>Adult and adolescent clinical studies ; Antidepressants ; Antidepressive Agents - therapeutic use ; Biological and medical sciences ; Clinical trials as a topic ; Cyclohexanols - therapeutic use ; Depression ; Depressive Disorder, Major - drug therapy ; Double-Blind Method ; Female ; Fluoxetine - therapeutic use ; Humans ; Inventory of depressive symptoms ; Major depressive disorder ; Male ; Medical sciences ; Mood disorders ; Neuropharmacology ; Outcomes assessment ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Ratings ; Severity of Illness Index ; Statistics as Topic ; Time Factors ; Treatment Outcome ; Venlafaxine Hydrochloride</subject><ispartof>Psychiatry research, 2010-05, Vol.177 (1), p.177-183</ispartof><rights>Elsevier Ltd</rights><rights>2010 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2010 Elsevier Ltd. All rights reserved.</rights><rights>2010 Elsevier Ireland Ltd. All rights reserved 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c621t-7987a7e72e6b83b64b60d5568c5a1f19627d77a3daed6e551791604a8e6f00863</citedby><cites>FETCH-LOGICAL-c621t-7987a7e72e6b83b64b60d5568c5a1f19627d77a3daed6e551791604a8e6f00863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165178110000545$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22806644$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20304503$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dunlop, Boadie W</creatorcontrib><creatorcontrib>Li, Thomas</creatorcontrib><creatorcontrib>Kornstein, Susan G</creatorcontrib><creatorcontrib>Friedman, Edward S</creatorcontrib><creatorcontrib>Rothschild, Anthony J</creatorcontrib><creatorcontrib>Pedersen, Ron</creatorcontrib><creatorcontrib>Ninan, Philip</creatorcontrib><creatorcontrib>Keller, Martin</creatorcontrib><title>Correlation between patient and clinician assessments of depression severity in the PREVENT study</title><title>Psychiatry research</title><addtitle>Psychiatry Res</addtitle><description>Abstract Background The degree of agreement between patient- and clinician-rated scales of depressive severity varies widely. This study analyzed agreement between commonly used depression rating scales in the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) trial. Methods The PREVENT trial was a multiphase, randomized, double-blind study of patients with recurrent major depressive disorder. This secondary analysis evaluated acute (10 weeks) and continuation phase (6 months) data. Pearson correlation coefficients at each acute-phase (weekly) and continuation-phase (monthly) visit were calculated for patient-rated (30-item Inventory of Depressive Symptomatology-Self-Rated [IDS-SR30] and clinician-rated (17-item Hamilton Rating Scale for Depression [HAM-D17] and Clinical Global Impressions-Severity [CGI-S]) measures and for response and remission. Results Data from 1,047 patients were analyzed. The respective correlation coefficients at baseline, week 10, and month 6 were: IDS-SR30: HAM-D17: 0.46, 0.75, 0.70; and for IDS-SR30: CGI-S 0.28, 0.67, 0.65. Agreement between IDS-SR30- and HAM-D17-defined remission and response was relatively poor: week 10, 0.52 and 0.34, respectively; month 6, 0.45 and 0.32, respectively. Conclusions These findings suggest that patient-rated measures of depression severity do not correspond strongly with clinician ratings, and are particularly poor prior to the initiation of treatment.</description><subject>Adult and adolescent clinical studies</subject><subject>Antidepressants</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Clinical trials as a topic</subject><subject>Cyclohexanols - therapeutic use</subject><subject>Depression</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Fluoxetine - therapeutic use</subject><subject>Humans</subject><subject>Inventory of depressive symptoms</subject><subject>Major depressive disorder</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mood disorders</subject><subject>Neuropharmacology</subject><subject>Outcomes assessment</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Ratings</subject><subject>Severity of Illness Index</subject><subject>Statistics as Topic</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Venlafaxine Hydrochloride</subject><issn>0165-1781</issn><issn>1872-7123</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUktv1DAQthAVXQp_ofKFY7a2k9jJpQKtFopUUQSFq-XYE9ZL1ok82UX59zhsX3DhZNnzPcbfDCHnnC054_JiuxxwspsIuBQsPTKxZKx6Rha8UiJTXOTPySIBy4yrip-Sl4hbxpjgdf2CnAqWs6Jk-YKYVR8jdGb0faANjL8AAh3SFcJITXDUdj54602gBhEQd6mAtG-pgyG548xDOED040R9oOMG6Ocv6-_rT7cUx72bXpGT1nQIr-_OM_Lt_fp2dZVd33z4uHp3nVkp-JipulJGgRIgmypvZNFI5spSVrY0vOW1FMopZXJnwEkoS65qLllhKpBt-rnMz8jlUXfYNztwNvUZTaeH6HcmTro3Xv9dCX6jf_QHnUtZqT8C8ihgY48YoX3gcqbn0PVW34eu59A1EzpZJ-L5U-cH2n3KCfDmDmDQmq6NJliPjzhRMSmLIuHeHnGQcjp4iBptGoQF5yPYUbve_7-Xy38kjgM03U-YALf9PoY0Bc01JoL-Oq_IvCE8LQcrizL_DTI4urk</recordid><startdate>20100515</startdate><enddate>20100515</enddate><creator>Dunlop, Boadie W</creator><creator>Li, Thomas</creator><creator>Kornstein, Susan G</creator><creator>Friedman, Edward S</creator><creator>Rothschild, Anthony J</creator><creator>Pedersen, Ron</creator><creator>Ninan, Philip</creator><creator>Keller, Martin</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20100515</creationdate><title>Correlation between patient and clinician assessments of depression severity in the PREVENT study</title><author>Dunlop, Boadie W ; Li, Thomas ; Kornstein, Susan G ; Friedman, Edward S ; Rothschild, Anthony J ; Pedersen, Ron ; Ninan, Philip ; Keller, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c621t-7987a7e72e6b83b64b60d5568c5a1f19627d77a3daed6e551791604a8e6f00863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Antidepressants</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Clinical trials as a topic</topic><topic>Cyclohexanols - therapeutic use</topic><topic>Depression</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Fluoxetine - therapeutic use</topic><topic>Humans</topic><topic>Inventory of depressive symptoms</topic><topic>Major depressive disorder</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mood disorders</topic><topic>Neuropharmacology</topic><topic>Outcomes assessment</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Ratings</topic><topic>Severity of Illness Index</topic><topic>Statistics as Topic</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Venlafaxine Hydrochloride</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dunlop, Boadie W</creatorcontrib><creatorcontrib>Li, Thomas</creatorcontrib><creatorcontrib>Kornstein, Susan G</creatorcontrib><creatorcontrib>Friedman, Edward S</creatorcontrib><creatorcontrib>Rothschild, Anthony J</creatorcontrib><creatorcontrib>Pedersen, Ron</creatorcontrib><creatorcontrib>Ninan, Philip</creatorcontrib><creatorcontrib>Keller, Martin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Psychiatry research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dunlop, Boadie W</au><au>Li, Thomas</au><au>Kornstein, Susan G</au><au>Friedman, Edward S</au><au>Rothschild, Anthony J</au><au>Pedersen, Ron</au><au>Ninan, Philip</au><au>Keller, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation between patient and clinician assessments of depression severity in the PREVENT study</atitle><jtitle>Psychiatry research</jtitle><addtitle>Psychiatry Res</addtitle><date>2010-05-15</date><risdate>2010</risdate><volume>177</volume><issue>1</issue><spage>177</spage><epage>183</epage><pages>177-183</pages><issn>0165-1781</issn><eissn>1872-7123</eissn><coden>PSRSDR</coden><abstract>Abstract Background The degree of agreement between patient- and clinician-rated scales of depressive severity varies widely. This study analyzed agreement between commonly used depression rating scales in the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) trial. Methods The PREVENT trial was a multiphase, randomized, double-blind study of patients with recurrent major depressive disorder. This secondary analysis evaluated acute (10 weeks) and continuation phase (6 months) data. Pearson correlation coefficients at each acute-phase (weekly) and continuation-phase (monthly) visit were calculated for patient-rated (30-item Inventory of Depressive Symptomatology-Self-Rated [IDS-SR30] and clinician-rated (17-item Hamilton Rating Scale for Depression [HAM-D17] and Clinical Global Impressions-Severity [CGI-S]) measures and for response and remission. Results Data from 1,047 patients were analyzed. The respective correlation coefficients at baseline, week 10, and month 6 were: IDS-SR30: HAM-D17: 0.46, 0.75, 0.70; and for IDS-SR30: CGI-S 0.28, 0.67, 0.65. Agreement between IDS-SR30- and HAM-D17-defined remission and response was relatively poor: week 10, 0.52 and 0.34, respectively; month 6, 0.45 and 0.32, respectively. Conclusions These findings suggest that patient-rated measures of depression severity do not correspond strongly with clinician ratings, and are particularly poor prior to the initiation of treatment.</abstract><cop>Kidlington</cop><pub>Elsevier Ireland Ltd</pub><pmid>20304503</pmid><doi>10.1016/j.psychres.2010.02.008</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-1781 |
| ispartof | Psychiatry research, 2010-05, Vol.177 (1), p.177-183 |
| issn | 0165-1781 1872-7123 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3668786 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult and adolescent clinical studies Antidepressants Antidepressive Agents - therapeutic use Biological and medical sciences Clinical trials as a topic Cyclohexanols - therapeutic use Depression Depressive Disorder, Major - drug therapy Double-Blind Method Female Fluoxetine - therapeutic use Humans Inventory of depressive symptoms Major depressive disorder Male Medical sciences Mood disorders Neuropharmacology Outcomes assessment Pharmacology. Drug treatments Psychiatric Status Rating Scales Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Ratings Severity of Illness Index Statistics as Topic Time Factors Treatment Outcome Venlafaxine Hydrochloride |
| title | Correlation between patient and clinician assessments of depression severity in the PREVENT study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T20%3A58%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20between%20patient%20and%20clinician%20assessments%20of%20depression%20severity%20in%20the%20PREVENT%20study&rft.jtitle=Psychiatry%20research&rft.au=Dunlop,%20Boadie%20W&rft.date=2010-05-15&rft.volume=177&rft.issue=1&rft.spage=177&rft.epage=183&rft.pages=177-183&rft.issn=0165-1781&rft.eissn=1872-7123&rft.coden=PSRSDR&rft_id=info:doi/10.1016/j.psychres.2010.02.008&rft_dat=%3Celsevier_pubme%3ES0165178110000545%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/20304503&rft_els_id=S0165178110000545&rfr_iscdi=true |